Clinical trials: Dementia Disorders
Agitation in Dementia
To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease
This study tests a medication called dronabinol in people with Alzheimer's disease. First, participants go through up to 4 weeks of screening. Then, over 2 weeks, the dose of the study drug is slowly increased.
- Trial name
- NCT07422311
- Testing
- Dronabinol Oral Solution
- Where
- Australia
- Volunteers
- 140 people
- Sponsor
- Benuvia Therapeutics Inc.
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Alzheimer Disease, Dementia of Alzheimer Type
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
- Trial name
- ACT-AD (NCT04491006)
- Testing
- ATH-1017
- Where
- 13 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- LeonaBio
Alzheimer's Disease
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a…
- Trial name
- NCT00810147
- Testing
- BMS-708163
- Where
- 41 sites in United States, Denmark and 2 more
- Volunteers
- 209 people
- Sponsor
- Bristol-Myers Squibb
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alzheimer Disease
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00104013
- Testing
- xaliproden (SR57746A)
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 1,455 people
- Sponsor
- Sanofi
Lymphoma, Solid Malignancy
PET Imaging of Subjects Using 124I-PU-AD
This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.
- Conditions
- Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
- Trial name
- NCT03371420
- Testing
- PU-AD, PET Scan, Blood Draws
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Samus Therapeutics, Inc.
Alzheimer Disease, Cognitive Change
Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease
In this study, it is aimed to compare the effects of cognitive exercises applied on long-term internet environment to the cognitive level of patients who received donepezil, memantine or donepezil / memantin combination therapy.
- Trial name
- NCT03954613
- Testing
- Ebicomb
- Where
- Turkey (Türkiye)
- Volunteers
- 198 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Alzheimer Disease
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
The study is designed as a classic, randomized, double blind, placebo controlled, parallel group study including one active dose of PU AD and matching placebo, designed to assess safety, tolerability and pharmacological effects…
- Trial name
- NCT04311515
- Testing
- Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Samus Therapeutics, Inc.
Alzheimer's Disease
A Safety Study of LY2811376 Single Doses in Healthy Subjects
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2811376 single doses, how the body handles the drug, and the drug's effect on the body.
- Trial name
- NCT00838084
- Testing
- LY2811376
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Substance Use Disorder (SUD)
A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication
This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances.
- Trial name
- NCT06629740
- Testing
- Measurements with a eHealth system
- Where
- Netherlands
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Kontigo Care AB
Frontotemporal Dementia
Epidemiological Study in FRONtoTemporal Dementia
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.
- Trial name
- EFRONT (NCT05075187)
- Testing
- Genetic Screening
- Where
- 37 sites in Belgium, Germany and 5 more
- Volunteers
- 2,287 people, healthy volunteers welcome
- Sponsor
- CENTOGENE GmbH Rostock
Alzheimer Disease, Gastric Retention
Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults
To assess how long memantine hydrochloride (HCl) (50 mg) extended release capsules stay in the stomach as determined by imaging assessment (MRI or abdominal ultrasound).
- Conditions
- Alzheimer Disease, Gastric Retention, Healthy
- Trial name
- NCT03711825
- Testing
- LYN-057, Imaging Assessment (MRI), Imaging Assessment (U/S)
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Lyndra Inc.
Alzheimer's Disease
Memantine and Validation of a New Alzheimer's Disease Scale
To validate a new Alzheimer's Disease scale against other rating tools in subjects with dementia of Alzheimer's type, treated with memantine.
- Trial name
- NCT00804271
- Testing
- memantine
- Where
- Germany
- Volunteers
- 487 people
- Sponsor
- Merz Pharmaceuticals GmbH
Schizophrenia
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia
- Trial name
- NCT00723606
- Testing
- Intramuscular ziprasidone mesylate, Intramuscular haloperidol
- Where
- 9 sites in China
- Volunteers
- 376 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dementia, Dementia Alzheimer Type
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
This is a human clinical study making a noninvasive measurement from a patient's eye to determine whether there is a quantitative difference in measurements between patients with and without the diagnosis of dementia.
- Trial name
- DLS (NCT06613971)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- MD Stem Cells
Alzheimer's Disease
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
This is a 96-week extension study of open-label simufilam 100 mg b.i.d. for mild-to-moderate Alzheimer's disease subjects who completed the Phase 2 study, PTI-125-04. The study will evaluate safety and long-term treatment.
- Trial name
- NCT05352763
- Testing
- simufilam
- Where
- 11 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer's Disease
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
- Trial name
- NCT05463731
- Testing
- Remternetug (IV), Remternetug (SC)
- Where
- 76 sites in United States, Japan
- Volunteers
- 1,667 people
- Sponsor
- Eli Lilly and Company
Cognitive Disorders
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate how much of the study drug gets into the brain.
- Trial name
- NCT00937846
- Testing
- GSK1034702
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.